Literature DB >> 2890295

Development of a single probe for documentation of chimerism following bone marrow transplantation.

P Yam1, L D Petz, S Ali, A D Stock, R B Wallace.   

Abstract

Although numerous genetic markers are available for studying chimerism after bone marrow transplantation (BMT), there remains a need for a practical and highly informative method that is applicable in the early posttransplantation period. Using DNA restriction-fragment-length polymorphisms (RFLPs), we have evaluated the feasibility of developing a single synthetic oligonucleotide probe to study post-BMT chimerism. We have thus tested three candidate probes, termed O-3315-32, O-3315-80, and O-AY-29, that are homologous to tandemly repetitive sequences. Our results demonstrated donor-specific and recipient-specific fragments in 11 of 11 HLA-matched sibling pairs tested using probes O-3315-32 and O-3315-80. When probe O-AY-29 was used, 14 of 17 sibling pairs showed both donor and recipient markers, one had only a recipient marker, and two were identical. We showed that each of the three synthetic probes was effective in documenting donor marrow engraftment, mixed hematopoietic chimerism, the patient's pre-BMT phenotype (by using cultured skin fibroblasts obtained after BMT), and the origin of the malignant hematopoietic cells (i.e., of donor or recipient origin) in patients who developed recurrent hematologic malignancy following BMT. Compared with the use of cloned genomic probes, there are several important advantages to the use of synthetic oligonucleotide probes in studying post-BMT chimerism. Synthetic probes have absolute hybridization specificity and can be designed to suit the purposes of an individual study, since they have adjustable specificity that can be altered by changes in the length of the probe and by changes in the hybridization temperature. A single synthetic probe analogous to several highly polymorphic loci can have a polymorphism information content sufficiently high so that all but a small percentage of BMT patients could be followed easily; for example, if a probe were complementary to three highly polymorphic unlinked loci, it would discriminate approximately 98% of sibling donor/recipient pairs. This would be accomplished using only one restriction-endonuclease digestion and only one gel electrophoresis. Since other genetic markers, e.g., red blood cell antigens, immunoglobulin allotypes, and chromosome analysis, are not uniformly informative and, in some cases, cannot be used in the early posttransplantation period, the use of synthetic oligonucleotide probes for analysis of DNA RFLP is emerging as the method of choice for studies of post-BMT chimerism. This method will allow for the development of new knowledge that has not been possible with previous methods.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890295      PMCID: PMC1684336     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.

Authors:  S J Forman; K G Blume; R A Krance; P J Miner; G E Metter; L R Hill; M R O'Donnell; A P Nademanee; D S Snyder
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

2.  Hypervariable 'minisatellite' regions in human DNA.

Authors:  A J Jeffreys; V Wilson; S L Thein
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

3.  Cytogenetic studies on recipients of allogeneic bone marrow transplants after fractionated total body irradiation.

Authors:  N Schmitz; E Gödde-Salz; H Löffler
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

Review 4.  Synthesis and use of synthetic oligonucleotides.

Authors:  K Itakura; J J Rossi; R B Wallace
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

5.  Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment length polymorphism.

Authors:  M D Minden; H A Messner; A Belch
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

6.  Donor cell leukemia developing six years after marrow grafting for acute leukemia.

Authors:  R P Witherspoon; W Schubach; P Neiman; P Martin; E D Thomas
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

7.  ABO-incompatible marrow transplants.

Authors:  W I Bensinger; C D Buckner; E D Thomas; R A Clift
Journal:  Transplantation       Date:  1982-04       Impact factor: 4.939

8.  A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia.

Authors:  W H Schubach; R Hackman; P E Neiman; G Miller; E D Thomas
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

Review 9.  Construction of a genetic linkage map in man using restriction fragment length polymorphisms.

Authors:  D Botstein; R L White; M Skolnick; R W Davis
Journal:  Am J Hum Genet       Date:  1980-05       Impact factor: 11.025

10.  Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms.

Authors:  D Ginsburg; J H Antin; B R Smith; S H Orkin; J M Rappeport
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

View more
  3 in total

1.  A rapid method for detection of Y-chromosomal DNA from dried blood specimens by the polymerase chain reaction.

Authors:  M Witt; R P Erickson
Journal:  Hum Genet       Date:  1989-06       Impact factor: 4.132

2.  Intrinsic polymorphism of variable number tandem repeat loci in the human genome.

Authors:  S Ali; R B Wallace
Journal:  Nucleic Acids Res       Date:  1988-09-12       Impact factor: 16.971

3.  Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

Authors:  Betul Oran; Sergio Giralt; Rima Saliba; Chitra Hosing; Uday Popat; Issa Khouri; Daniel Couriel; Muzaffar Qazilbash; Paolo Anderlini; Partow Kebriaei; Shubhra Ghosh; Antonio Carrasco-Yalan; Ernesto de Meis; Athanasios Anagnostopoulos; Michele Donato; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-08       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.